RGCC and cancer: Various studies have described an aberrant RGC-32 mRNA expression in human cancers: up-regulation in colon (79, 80), ovarian (81, 82), breast (79, 83, 84) and prostate (79) cancers and lymphomas (85, 86) and downregulation in glioblastomas (87), astrocytomas (88), adrenocortical carcinomas (89), and multiple myelomas (90).